AFYX Therapeutics (formerly known as Dermtreat ApS) is a biopharmaceutical company focused on innovative approaches to treat mucosal diseases. Its Rivelin patch is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and high flexibility, conforming to the mucosal surface.
|Employees (est.) (Sept 2021)||9||(-10%)|
AFYX Therapeutics total Funding
AFYX Therapeutics latest funding size
Time since last funding
|2 years ago|
AFYX Therapeutics investors
|Sofinnova Ventures, Novo Seeds, Lundbeckfonden Emerge|
When was AFYX Therapeutics founded?
AFYX Therapeutics was founded in 2014.
Who are AFYX Therapeutics key executives?
AFYX Therapeutics's key executives are Nishan de Silva, Lars Siim Madsen and Kristine Peterson.
How many employees does AFYX Therapeutics have?
AFYX Therapeutics has 9 employees.
Who are AFYX Therapeutics competitors?
Competitors of AFYX Therapeutics include Kartos Therapeutics, Fysius Rugexperts and Right To Care.
Where is AFYX Therapeutics headquarters?
AFYX Therapeutics headquarters is located at Lergravsvej 57, 2 . tv, København.
Where are AFYX Therapeutics offices?
AFYX Therapeutics has offices in København and San Diego.
How many offices does AFYX Therapeutics have?
AFYX Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies